Clinical Efficacy of Tanreqing Injection Combined with Western Medicine in Treatment of Pneumonia Caused by Multi-drug Resistant Bacteria in Elderly Patients / 中国实验方剂学杂志

Objective:To observe the clinical effect of Tanreqing injection combined with western medicine on pneumonia caused by multi-drug resistant bacteria （MDRB） in elderly patients. Method:A total of 140 MDRB-induced pneumonia inpatients with the syndrome of phlegm-heat obstructing lung in the intensive care unit （ICU） of Dalian Hospital of Traditional Chinese Medicine from December 2018 to December 2020 were divided into an observation group （70 cases） and a control group （70 cases）） according to the random number table method. The patients in the control group received conventional treatment by western medicine， and those in the observation group received conventional treatment by western medicine combined with Tanreqing injection. The course of treatment was 7 days. The main efficacy indexes of the two groups before and after treatment were recorded，including the total clinical efficacy of traditional Chinese medicine （TCM） syndrome，total TCM syndrome score，clinical pulmonary infection score （CPIS）， and the clearance rate of MDRB. Secondary efficacy indexes included temperature recovery and cough remission time，procalcitonin （PCT），C-reactive protein （CRP），white blood cell count （WBC），interleukin-6 （IL-6），interleukin-8 （IL-8）， and oxygen partial pressure （PO₂）. Result:The total effective rates of the observation group and the control group were 90.00% （63/70） and 75.70% （53/70），respectively，and the observation group had superior curative efficacy （<italic>Z</italic>=-2.147，<italic>P</italic><0.05）. After treatment，CPIS and total TCM syndrome scores in both groups decreased compared with those before treatment，and the decrease was more significant in the observation group （<italic>P</italic><0.01）. The clearance rate of MDRB in the observation group was 67.1% （47/70），superior to 48.6% （34/70） in the control group （<italic>χ</italic>²=4.951，<italic>P</italic><0.05）. The temperature recovery and cough remission time in the observation group was shorter than that in the control group （<italic>P</italic><0.01）. After treatment，the levels of PCT，CRP，WBC，IL-6， and IL-8 in both groups were reduced compared with those before treatment，while the levels of PO₂ increased （<italic>P</italic><0.01）. The improvement of various inflammatory indexes and the PO₂ level in the observation group was better than that in the control group （<italic>P</italic><0.01）. Conclusion:The clinical efficacy of Tanreqing injection combined with western medicine in the treatment of MDRB-induced pneumonia in elderly patients is significant，which can control infection，reduce inflammatory damage，improve the clearance rate of MDRB and PO₂，and alleviate clinical symptoms. It is worthy of clinical application.

Expert consensus statement on Pudilan Xiaoyan Oral Liquid in clinical practice / 中国中药杂志

Pudilan Xiaoyan Oral Liquid has effects in clearing away heat and detoxifying,and is used to treat pharynx and throat swelling caused by the syndrome of excessive heat and toxin accumulation. Its efficacy is to relieve swelling and pain( redness,swelling and hot pain). It is included in the Chinese Pharmacopoeia of 2015 Edition,and has been listed in provincial health insurance directories of Shaanxi,Jiangsu,Liaoning,Hunan,Tianjin,Xinjiang and Hebei. It has been recommended by health departments of Beijing,Chongqing and other provinces as a preferred drug for the prevention and treatment of H1 N1 and HFMD,and listed in the diagnosis and Treatment Guide of HFMD by the Ministry of Health,the Clinical Application Guide of Chinese Patent Medicine edited by the Lung Department Disease Branch of China Association of Chinese Medicine,and the Clinical Practice Guide of Single Administration/Combined Administration of Antibiotics in Treatment of Common Infectious Diseases by China Association of Chinese Medicine. To further improve the clinician's understanding of drugs and better guide the rational clinical application,we invited front-line clinical experts from respiratory department,infectious department and dermatology of traditional Chinese and Western medicine to develop and compile the expert consensus. The consensus fully considered the clinical evidence and the expert clinical experience to give recommendations for clinical problems with evidence support and consensus suggestions for clinical problems without evidence support by the nominal group method.This consensus is based on clinical research evidence and expert experience in a simple and clear format,which provides a preliminary reference for the clinical use of the drug.